The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

- As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval - Attruby (acoramidis), the first and only near-complete TTR ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

To help BridgeBio ramp up for the launch of three new medicines, plus approved ATTR-CM med Attruby, Sixth Street and HealthCare Royalty have agreed to invest up to $1 billion in the California biotech ...

BridgeBio's forward-looking statements in the press release reflect the company's expectations for the commercial success of Attruby, the progression of its clinical trials, and the potential for its ...

BBIO’s Attruby (Acoramidis) delivers early, durable reductions in cumulative cardiovascular events. This candidate positions BBIO against Pfizer’s Tafamidis and Alnylam’s Amvuttra. Its US uptake keeps ...

BridgeBio reports strong demand for Attruby post-FDA approval and enrollment completion in three Phase 3 trials, with significant financial backing. BridgeBio Pharma, Inc. announced significant ...

$154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectively ...

Additionally, the company reported U.S. Attruby sales of $108 million, slightly ahead of Leerink Partners’ estimate of $105 million and above the consensus of $102 million. Leerink Partners ...

$194.5 million in total first quarter revenues, comprised of $180.6 million of U.S. Attruby® net product revenue, with strong prescribing growth and patient persistence driving continued commercial ...

BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the stocks with explosive growth potential. On February 24, BridgeBio Pharma reported a transformative full-year 2025, marked by a surge in total revenue ...